Pink Sheet reporter and editors consider the financial and educational background of FDA commissioner nominee Heidi Overton and recent changes to COVID-19 vaccine postmarketing trials.
Pink Sheet reporter and editors consider the financial and educational background of FDA commissioner nominee Heidi Overton and recent changes to COVID-19 vaccine postmarketing trials.